儿童标危B细胞急性淋巴细胞白血病结局:COG AALL0331试验结果
COG AALL0331研究纳入5377例儿童标危B细胞急性淋巴细胞白血病患者,评估强化巩固治疗是否改善结局。结果显示6年无事件生存率88.96%±0.46%,总生存率95.54%±0.31%;标危平均组强化巩固与标准巩固的6年持续完全缓解和总生存无显著差异。
要点
- 标危平均组强化巩固未改善6年持续完全缓解或总生存。
- 诱导后MRD 0.01%至<0.1%者结局较差,强化巩固未改善。
- 标危高危组接受全程COG强化BFM方案,6年持续完全缓解85.55%±1.49%。
核心结论
- AALL0331入组>5000例标危ALL儿童6年总生存率超过95%。
- 标危平均组强化巩固未改善持续完全缓解或总生存,即使MRD较高者亦无改善。
研究设计与样本
- COG AALL0331试验于2005至2010年入组5377例患者。
- 所有患者接受地塞米松、长春新碱和培门冬酶三药诱导后分为标危低、平均和高危。
- 标危平均组随机接受4周标准巩固或8周强化BFM巩固;标危高危组非随机接受全程COG强化BFM方案。
主要发现
- 全部入组患者6年无事件生存率88.96%±0.46%,总生存率95.54%±0.31%。
- 标危平均组标准巩固与强化巩固6年总生存分别为95.8%±0.8%与95.2%±0.8%(P=1.0)。
- 635例非随机标危高危患者6年持续完全缓解85.55%±1.49%,总生存92.97%±1.08%。
临床怎么用
- 标危平均组不建议常规采用8周强化BFM巩固替代4周标准巩固。
- 诱导后MRD 0.01%至<0.1%的标危平均患者需关注较差结局,强化巩固未显示获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Children's Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (SR) ALL. PATIENTS AND METHODS: AALL0331 enrolled 5,377 patients between 2005 and 2010. All patients received a 3-drug induction with dexamethasone, vincristine, and pegaspargase (PEG) and were then classified as SR low, SR average, or SR high. Patients with SR-average disease were randomly assigned to receive either standard 4-week consolidation (SC) or 8-week intensified augmented Berlin-Frankfurt-Münster (BFM) consolidation (IC). Those with SR-high disease were nonrandomly assigned to the full COG-augmented BFM regimen, including 2 interim maintenance and delayed intensification phases. RESULTS: The 6-year event-free survival (EFS) rate for all patients enrolled in AALL0331 was 88.96% ± 0.46%, and overall survival (OS) was 95.54% ± 0.31%. For patients with SR-average disease, the 6-year continuous complete remission (CCR) and OS rates for SC versus IC were 87.8% ± 1.3% versus 89.1% ± 1.2% (P = .52) and 95.8% ± 0.8% versus 95.2% ± 0.8% (P = 1.0), respectively. Those with SR-average disease with end-induction minimal residual disease (MRD) of 0.01% to < 0.1% had an inferior outcome compared with those with lower MRD and no improvement with IC (6-year CCR: SC, 77.5% ± 4.8%; IC, 77.1% ± 4.8%; P = .71). At 6 years, the CCR and OS rates among 635 nonrandomly treated patients with SR-high disease were 85.55% ± 1.49% and 92.97% ± 1.08%, respectively. CONCLUSION: The 6-year OS rate for > 5,000 children with SR ALL enrolled in AALL0331 exceeded 95%. The addition of IC to treatment for patients with SR-average disease did not improve CCR or OS, even in patients with higher MRD, in whom it might have been predicted to provide more value. The EFS and OS rates are excellent for this group of patients with SR ALL, with particularly good outcomes for those with SR-high disease.
引用
- Maloney KW, Devidas M, Wang C, et al. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2019. PMID: 31825704. doi:10.1200/JCO.19.01086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。